These sales are too small to signal anything about the company's outlook. Monitor for any material insider buying or larger sales (>0.5% of market cap) for a meaningful signal.
Price Chart
Executive Summary
Two C-suite insiders at Enliven Therapeutics (ELVN) sold a combined $310K in open-market sales on August 17, 2026. The CFO sold $352K total (two trades) and the CMO sold $293K total (two trades, plus derivative exercises). At a $4.4B market cap, these sales represent ~0.007% of market cap — a trivial amount that is routine and non-informative. The derivative exercises by the CMO are non-cash events and do not change the analysis. The cluster is a sell, but the dollar value is immaterial relative to company size, and the sales likely reflect routine portfolio diversification or tax planning, not a bearish signal.
Key Financial Metrics
Key Facts
- CFO Benjamin Hohl sold 4,630 shares ($270K) and 1,388 shares ($82K) on August 17, 2026.
- CMO Helen Louise Collins sold 1,100 shares ($65K) and 3,900 shares ($228K) on August 17, 2026.
- CMO Collins also exercised derivatives for 5,000 shares at $0 and 5,000 shares at $2.48 — non-cash events.
- Total open-market sales: ~$645K across both insiders, representing ~0.015% of $4.4B market cap.
- No insider buying in the cluster — net direction is selling, but at a trivial proportion of market cap.
Financial Impact
Total insider sales of ~$645K, or ~0.015% of $4.4B market cap — immaterial.
Risk Factors
- Insider sales could accelerate if the stock continues to rise, but current levels are routine.
- No fundamental catalyst identified — the cluster is purely administrative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ELVN-1787198717420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.29 (−1.53%) |
Oct 19, 2026 6d ago | 144 | $41.25 | awaiting T+5 | — | $41.29 (+0.10%) |
Oct 16, 2026 9d ago | 3 | $38.70 | awaiting T+5 | — | $41.29 (+6.69%) |
Oct 14, 2026 11d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.29 (+4.98%) |
Sep 21, 2026 4w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.29 (−14.32%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.29 (−30.39%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.29 (−29.98%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.29 (−30.51%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.29 (−21.87%) |
Jun 22, 2026 17w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.29 (−15.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers